The Founders of Betagenon have over 30 years of experience of internationally competitive research on β-cell function and diabetes. The management and board of directors have extensive experience from both biopharmaceutical and biotechnology companies. Betagenon has access to a team of specialists in clinical trials of diabetic kidney disease, heart failure, diabetes, liver and microvascular disease.
James Hall BM, BCh, D.Phil has joined from Maj 2021 as new CEO. Dr. Hall brings extensive senior healthcare and life science experience, including 12 years with AstraZeneca. While there, he held a number of commercial, R&D and Business Development roles, including VP Global Marketing for the CV/GI Therapy Area, Global Product VP for Crestor and VP Evaluation for the CV/Metabolism/Renal Therapy Area. Prior to this he was a member of the Pharmaceutical /Medical Products practice at McKinsey & Co. He has a BM, BCh in Clinical Medicine and a D.Phil in Cell Physiology from Oxford University where he was a Rhodes Scholar.
Helena Edlund, Ph.D., Founder, Vice President, Head of Discovery, Professor in Molecular Developmental Biology at Umeå Center for Molecular Medicine, University of Umeå. She has been a Visiting Professor at the Diabetes Research Institute, University of Miami School of Medicine, Miami, US. Dr. H. Edlund has provided seminal information on transcription and signalling factors that control key aspects of pancreas development and beta-cell function. Dr. H. Edlund’s discoveries have raised considerable international recognition and have been honored by numerous national and international awards. Presently, Dr. H. Edlund heads a research team that uses genetic approaches and classical embryological techniques to study pancreas development and beta-cell function. Dr. H.Edlund is a member of the Swedish Royal Academy of Sciences and of EMBO. She has served on the scientific advisory board of Ontogeny Inc., Cambridge, USA.
Thomas Edlund, Ph.D., Prof. Founder, Chief Scientific Officer. Professor in Molecular Genetics, University of Umeå. He was a co-founder of the biotech companies Symbicom AB and Uman Genomics AB and he has served on the scientific advisory board of Ontogeny Inc. Cambridge, USA. He has extensive experience of scientific strategy in biotech companies, in fundraising and other business activities. He was a Post-doc in Prof.William Rutter’s laboratory at UCSF, USA. He is an international renowned scientist in the study of the mechanism of development of the central nervous system and the mammalian pancreas and of the regulation of insulin gene expression. He is a member of the Swedish Royal Academy of Sciences and of EMBO and he has been honored by numerous national and international awards.
Olof Karlsson, MD, Ph.D., Founder, served as CEO between 2001-10. Prior to joining Betagenon Dr Karlsson worked at Novartis. In the field of diabetes he was working in the international clinical team on the insulin secretagogue, nateglinide. He also participated in the business development, marketing and sales of nateglinide. He has also worked on other diabetes projects such as dipeptidyl peptidase IV inhibitors. He received his PhD in molecular biology at the University of Umeå where he studied cell-specific insulin gene transcription and postgraduate training at UCSF, USA.